Brevan Howard Capital Management LP Buys 16,725 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Brevan Howard Capital Management LP boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 27.2% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 78,104 shares of the company's stock after purchasing an additional 16,725 shares during the period. Brevan Howard Capital Management LP's holdings in Hims & Hers Health were worth $1,889,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership grew its holdings in Hims & Hers Health by 192.0% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after purchasing an additional 4,145,305 shares during the period. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 11.1% during the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after acquiring an additional 2,020,722 shares during the period. Yong Rong HK Asset Management Ltd acquired a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $41,104,000. Renaissance Technologies LLC raised its stake in Hims & Hers Health by 29.0% in the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after acquiring an additional 1,562,302 shares during the period. Finally, Invesco Ltd. lifted its holdings in Hims & Hers Health by 613.9% during the 4th quarter. Invesco Ltd. now owns 1,277,026 shares of the company's stock valued at $30,878,000 after purchasing an additional 1,098,148 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $49.80 on Wednesday. Hims & Hers Health, Inc. has a 1 year low of $11.64 and a 1 year high of $72.98. The stock has a market capitalization of $11.06 billion, a price-to-earnings ratio of 113.19 and a beta of 1.84. The company's 50 day simple moving average is $32.39 and its 200 day simple moving average is $31.82.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.20 earnings per share for the quarter, topping the consensus estimate of $0.12 by $0.08. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. During the same period in the prior year, the company earned $0.05 EPS. Hims & Hers Health's revenue for the quarter was up 110.7% on a year-over-year basis. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Activity

In related news, insider Soleil Boughton sold 4,152 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $60.69, for a total transaction of $251,984.88. Following the sale, the insider now owns 157,345 shares of the company's stock, valued at $9,549,268.05. This trade represents a 2.57 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total value of $7,465,960.29. Following the completion of the transaction, the chief executive officer now directly owns 97,687 shares of the company's stock, valued at approximately $5,692,221.49. The trade was a 56.74 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 650,500 shares of company stock worth $25,790,311. Corporate insiders own 17.71% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Bank of America upped their price objective on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a report on Tuesday, April 29th. Needham & Company LLC reissued a "buy" rating and issued a $61.00 price target on shares of Hims & Hers Health in a report on Tuesday. Citigroup restated a "sell" rating and issued a $30.00 price target (up from $25.00) on shares of Hims & Hers Health in a research note on Tuesday. BTIG Research began coverage on Hims & Hers Health in a research report on Tuesday, January 7th. They set a "buy" rating and a $35.00 price objective on the stock. Finally, Truist Financial reduced their target price on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $37.67.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.